258 related articles for article (PubMed ID: 29738821)
1. Discovery and development of sGC stimulators for the treatment of pulmonary hypertension and rare diseases.
Sandner P; Becker-Pelster EM; Stasch JP
Nitric Oxide; 2018 Jul; 77():88-95. PubMed ID: 29738821
[TBL] [Abstract][Full Text] [Related]
2. From molecules to patients: exploring the therapeutic role of soluble guanylate cyclase stimulators.
Sandner P
Biol Chem; 2018 Jun; 399(7):679-690. PubMed ID: 29604206
[TBL] [Abstract][Full Text] [Related]
3. Soluble guanylate cyclase stimulators in pulmonary hypertension.
Stasch JP; Evgenov OV
Handb Exp Pharmacol; 2013; 218():279-313. PubMed ID: 24092345
[TBL] [Abstract][Full Text] [Related]
4. sGC stimulators: Evidence for riociguat beyond groups 1 and 4 pulmonary hypertension.
Benza R; Mathai S; Nathan SD
Respir Med; 2017 Jan; 122 Suppl 1():S28-S34. PubMed ID: 27890470
[TBL] [Abstract][Full Text] [Related]
5. The nitric oxide-soluble guanylate cyclase-cGMP pathway in pulmonary hypertension: from PDE5 to soluble guanylate cyclase.
Benza RL; Grünig E; Sandner P; Stasch JP; Simonneau G
Eur Respir Rev; 2024 Jan; 33(171):. PubMed ID: 38508664
[TBL] [Abstract][Full Text] [Related]
6. The Potential of sGC Modulators for the Treatment of Age-Related Fibrosis: A Mini-Review.
Sandner P; Berger P; Zenzmaier C
Gerontology; 2017; 63(3):216-227. PubMed ID: 27784018
[TBL] [Abstract][Full Text] [Related]
7. Anti-fibrotic effects of soluble guanylate cyclase stimulators and activators: A review of the preclinical evidence.
Sandner P; Stasch JP
Respir Med; 2017 Jan; 122 Suppl 1():S1-S9. PubMed ID: 28341058
[TBL] [Abstract][Full Text] [Related]
8. Soluble Guanylate Cyclase Stimulators and Activators: Novel Therapies for Pulmonary Vascular Disease or a Different Method of Increasing cGMP?
Koress C; Swan K; Kadowitz P
Curr Hypertens Rep; 2016 Apr; 18(5):42. PubMed ID: 27118316
[TBL] [Abstract][Full Text] [Related]
9. Soluble Guanylate Cyclase Stimulators and Activators.
Sandner P; Zimmer DP; Milne GT; Follmann M; Hobbs A; Stasch JP
Handb Exp Pharmacol; 2021; 264():355-394. PubMed ID: 30689085
[TBL] [Abstract][Full Text] [Related]
10. Soluble guanylate cyclase stimulator riociguat and phosphodiesterase 5 inhibitor sildenafil ameliorate pulmonary hypertension due to left heart disease in mice.
Pradhan K; Sydykov A; Tian X; Mamazhakypov A; Neupane B; Luitel H; Weissmann N; Seeger W; Grimminger F; Kretschmer A; Stasch JP; Ghofrani HA; Schermuly RT
Int J Cardiol; 2016 Aug; 216():85-91. PubMed ID: 27140341
[TBL] [Abstract][Full Text] [Related]
11. Riociguat: Mode of Action and Clinical Development in Pulmonary Hypertension.
Ghofrani HA; Humbert M; Langleben D; Schermuly R; Stasch JP; Wilkins MR; Klinger JR
Chest; 2017 Feb; 151(2):468-480. PubMed ID: 27263466
[TBL] [Abstract][Full Text] [Related]
12. Riociguat: a soluble guanylate cyclase stimulator for the treatment of pulmonary hypertension.
Lian TY; Jiang X; Jing ZC
Drug Des Devel Ther; 2017; 11():1195-1207. PubMed ID: 28458514
[TBL] [Abstract][Full Text] [Related]
13. Soluble guanylate cyclase: a new therapeutic target for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.
Dasgupta A; Bowman L; D'Arsigny CL; Archer SL
Clin Pharmacol Ther; 2015 Jan; 97(1):88-102. PubMed ID: 25670386
[TBL] [Abstract][Full Text] [Related]
14. Novel sGC Stimulators and sGC Activators for the Treatment of Heart Failure.
Breitenstein S; Roessig L; Sandner P; Lewis KS
Handb Exp Pharmacol; 2017; 243():225-247. PubMed ID: 27900610
[TBL] [Abstract][Full Text] [Related]
15. Nitric oxide-independent stimulation of soluble guanylate cyclase with BAY 41-2272 in cardiovascular disease.
Boerrigter G; Burnett JC
Cardiovasc Drug Rev; 2007; 25(1):30-45. PubMed ID: 17445086
[TBL] [Abstract][Full Text] [Related]
16. Hemodynamic Effects of a Soluble Guanylate Cyclase Stimulator, Riociguat, and an Activator, Cinaciguat, During NO-Modulation in Healthy Pigs.
Næsheim T; How OJ; Myrmel T
J Cardiovasc Pharmacol Ther; 2021 Jan; 26(1):75-87. PubMed ID: 32662299
[TBL] [Abstract][Full Text] [Related]
17. Rationale and study design of RESPITE: An open-label, phase 3b study of riociguat in patients with pulmonary arterial hypertension who demonstrate an insufficient response to treatment with phosphodiesterase-5 inhibitors.
Hoeper MM; Klinger JR; Benza RL; Simonneau G; Langleben D; Naeije R; Corris PA
Respir Med; 2017 Jan; 122 Suppl 1():S18-S22. PubMed ID: 27887774
[TBL] [Abstract][Full Text] [Related]
18. Riociguat for the treatment of pulmonary hypertension.
Hambly N; Granton J
Expert Rev Respir Med; 2015; 9(6):679-95. PubMed ID: 26599488
[TBL] [Abstract][Full Text] [Related]
19. The chemistry and biology of soluble guanylate cyclase stimulators and activators.
Follmann M; Griebenow N; Hahn MG; Hartung I; Mais FJ; Mittendorf J; Schäfer M; Schirok H; Stasch JP; Stoll F; Straub A
Angew Chem Int Ed Engl; 2013 Sep; 52(36):9442-62. PubMed ID: 23963798
[TBL] [Abstract][Full Text] [Related]
20. The Impact of the Nitric Oxide (NO)/Soluble Guanylyl Cyclase (sGC) Signaling Cascade on Kidney Health and Disease: A Preclinical Perspective.
Krishnan SM; Kraehling JR; Eitner F; Bénardeau A; Sandner P
Int J Mol Sci; 2018 Jun; 19(6):. PubMed ID: 29890734
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
